Efektivitas Citicoline terhadap Perbaikan Status Fungsional dan Gangguan Neurologis pada Pasien dengan Stroke Perdarahan Intraserebral Supratentorial Akut
DOI:
https://doi.org/10.55175/cdk.v51i1.978Kata Kunci:
Citicoline, perdarahan intraserebralAbstrak
Perdarahan intraserebral supratentorial merupakan jenis stroke terbanyak kedua dan berpotensi memiliki prognosis buruk. Citicoline banyak diteliti untuk stroke iskemik, namun belum banyak buktinya untuk stroke perdarahan. Studi ini bertujuan untuk menelaah kritis bukti ilmiah terkait efektivitas citicoline untuk perbaikan status fungsional dan gangguan neurologis pasien stroke perdarahan supratentorial. Penelusuran artikel menggunakan 5 basis data: PubMed, Embase, Cochrane, Scopus, dan EBSCOHost. Dari 802 studi yang diidentifikasi awal, 5 studi diseleksi untuk telaah kritis. Studi Zang menunjukkan bahwa citicoline memberikan perbaikan skor NIHSS (p=0,015) dan indeks Barthel (p=0,001) secara signifikan. Studi Mousavi menunjukkan perbedaan signifikan perbaikan indeks Barthel (p=0,008) antara citicoline dan kontrol, namun tidak ada perbedaan dibandingkan sebelum terapipada kedua kelompok. Studi Iranmanesh menunjukkan perbaikan kekuatan motorik setelah pemberian citicoline (p=0,019). Studi Chua menunjukkan perbaikan indeks Barthel pada evaluasi 3 bulan setelah pemberian citicoline (p<0,05), namun tidak ada perbaikan signifikan pada skala mRS dan skor NIHSS. Studi Secades menunjukkan perbaikan signifikan pada skor NIHSS setelah pemberian citicoline (p<0,001), namun tidak memiliki perbedaan yang bermakna dibandingkan kontrol. Citicoline memiliki potensi meningkatkan mobilitas pasien pada stroke perdarahan intraserebral supratentorial, namun dalam hal perbaikan status fungsional dan gangguan neurologis memerlukan penelitian lebih lanjut.
Unduhan
Referensi
Feigin VL, Brainin M, Norrving B, Martins S, Sacco RL, Hacke W, et al. World Stroke Organization (WSO): Global stroke fact sheet 2022. Internat J Stroke. 2022;17(1):18–29.
Feigin VL, Stark BA, Johnson CO, Roth GA, Bisignano C, Abady GG, et al. Global, regional, and national burden of stroke and its risk factors, 1990–2019: A systematic analysis for the global burden of disease study 2019. Lancet Neurol. 2021;20(10):795–820.
Boehme AK, Esenwa C, Elkind MSV. Stroke risk factors, genetics, and prevention. Circ Res. 2017;120(3):472–95.
Murphy SJX, Werring DJ. Stroke: Causes and clinical features. Medicine (Abingdon) 2020;48(9):561–6.
Patel VD, Garcia RM, Swor DE, Liotta EM, Maas MB, Naidech A. Natural history of infratentorial intracerebral hemorrhages: two subgroups with distinct presentations and outcomes. J Stroke Cerebrovasc Dis. 2020;29(8):104920.
Kirkman MA, Smith M. Supratentorial intracerebral hemorrhage: A review of the underlying pathophysiology and its relevance for multimodality neuromonitoring in neurointensive care. J Neurosurg Anesthesiol. 2013;25(3):228.
Secades JJ, Alvarez-Sabín J, Castillo J, Díez-Tejedor E, Martínez-Vila E, Rios J, et al. Citicoline for acute ischemic stroke: A systematic review and formal meta-analysis of randomized, double-blind, and placebo-controlled trials. J Stroke Cerebrovasc Dis. 2016 Aug;25(8):1984–96.
Martí-Carvajal AJ, Valli C, Martí-Amarista CE, Solà I, Martí-Fàbregas J, Cosp XB. Citicoline for treating people with acute ischemic stroke. Cochrane Database Syst Rev. 2020 Aug 29;8(8):CD013066.
Perna R, Temple J. Rehabilitation outcomes: Ischemic versus hemorrhagic strokes. Behav Neurol. 2015;2015:891651.
OCEBM Levels of evidence - centre for evidence-based medicine. University of Oxford [Internet]. 2011 [cited 2022 Jun 3]. Available from: https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebm-levels-of-evidence.
Critical appraisal tools - Centre for evidence-based medicine. University of Oxford [Internet]. [cited 2023 Jun 25]. Available from: https://www.cebm.ox.ac.uk/resources/ebm-tools/critical-appraisal-tools.
Zang J, Xian LA, Qi L. The cytological mechanism and effects of hypertensive cerebral hemorrhage treatment by citicoline on serum gfap and copeptin level. Eur J Inflamm. 2019;17:2058739219867244.
Mousavi S, Zare M, Khorvash F, Nikbakht K. Evaluation of citicholine effect in acute phase of supratentorial hemorrhage: A randomized placebocontrolled clinical trial. J Cell Tissue Res. 2009;9:1773–6.
Iranmanesh F, Vakilian A. Efficiency of citicoline in increasing muscular strength of patients with nontraumatic cerebral hemorrhage: A doubleblind randomized clinical trial. J Stroke Cerebrovasc Dis. 2008;17(3):153–5.
Chua RH. Role of intravenous citicoline for supratentorial hemorrhage. Cerebrovascular diseases. 2007 May 30;23(Suppl 2):1–147.
Secades JJ, Ðlvarez-Sabín J, Rubio F, Lozano R, Dávalos A, Castillo J; Trial Investigators. Citicoline in intracerebral haemorrhage: A double-blind, randomized, placebo-controlled, multi-centre pilot study. Cerebrovasc Dis. 2006;21(5–6):380–5.
Grieb P. Neuroprotective properties of citicoline: Facts, doubts and unresolved issues. Cns drugs 2014;28(3):185–93.
Jasielski P, Piędel F, Piwek M, Rocka A, Petit V, Rejdak K. Application of citicoline in neurological disorders: A systematic review. Nutrients 2020 Oct 12;12(10):3113. doi: 10.3390/nu12103113.
Roy P, Tomassoni D, Nittari G, Traini E, Amenta F. Effects of choline containing phospholipids on the neurovascular unit: A review. Front Cell Neurosci. 2022;16:988759.
Conant R, Schauss AG. Therapeutic applications of citicoline for stroke and cognitive dysfunction in the elderly: A review of the literature. Altern Med Rev. 2004;9(1):17–31.
Kuriakose D, Xiao Z. Pathophysiology and treatment of stroke: present status and future perspectives. Int J Mol Sci. 2020 Oct 15;21(20):7609. doi: 10.3390/ijms21207609.
McGlade E, Agoston AM, DiMuzio J, Kizaki M, Nakazaki E, Kamiya T, et al. The effect of citicoline supplementation on motor speed and attention in adolescent males. J Atten Disord. 2019;23(2):121–34.
Senn R, Elkind MS, Montaner J, Christ-Crain M, Katan M. Potential role of blood biomarkers in the management of nontraumatic intracerebral hemorrhage. Cerebrovasc Dis. 2014;38(6):395-409. doi: 10.1159/000366470.
Alvarez-Sabín J, Román GC. The role of citicoline in neuroprotection and neurorepair in ischemic stroke. Brain Sci. 2013 Sep 23;3(3):1395-414. doi: 10.3390/brainsci3031395.
Liu F, Tsang RC, Zhou J, Zhou M, Zha F, Long J, et al. Relationship of barthel index and its short form with the modified rankin scale in acute stroke patients. J Stroke Cerebrovasc Dis. 2020 Sep;29(9):105033. doi: 10.1016/j.jstrokecerebrovasdis.2020.105033.
Davis AG, Nightingale S, Springer PE, Solomons R, Arenivas A, Wilkinson RJ, et al. Neurocognitive and functional impairment in adult and paediatric tuberculous meningitis. Wellcome Open Res. 2019 Nov 13;4:178. doi: 10.12688/wellcomeopenres.15516.1.
Cohen RA, Browndyke JN, Moser DJ, Paul RH, Gordon N, Sweet L. Long-term citicoline (cytidine diphosphate choline) use in patients with vascular dementia: Neuroimaging and neuropsychological outcomes. Cerebrovasc Dis. 2003;16(3):199-204. doi: 10.1159/000071116.
Shokouhi G, Haghjoo AG, Sattarnezhad N, Asghari M, Sattarnezhad A, Asghari A, et al. Effects of citicoline on level of consciousness, serum level of fetuin-a and matrix gla-protein (mgp) in trauma patients with diffuse axonal injury (dai) and gcs≤8. Ulus Travma Acil Cerrahi Derg. 2014 Nov;20(6):410-6. doi: 10.5505/tjtes.2014.05769.
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2024 Ariel Valentino Soetedjo
Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.
